Azurity Pharmaceuticals Receives FDA Approval for Lamlique™ (lamotrigine) oral suspension
Ready-to-use oral liquid formulation provides an additional treatment option for appropriate patients Ready-to-use oral liquid formulation provides an additional treatment option for appropriate patients
Short extract only — this publisher licenses its text. Read the full release at the source.
More from Commercial newswire
- BLAIZE HOLDINGS DEADLINE ONE WEEK AWAY: Bragar Eagel & Squire, P.C. Reminds Blaize Holdings, Inc. Investors to Contact the Firm Regarding Their Rights Before October 5th
- Rancho Bernardo Dentistry Releases Patient Guide Comparing Professional Teeth Whitening and At-Home Kits
- Acocelli Law, PLLC and Long Law, LLC Announce Agreement to Resolve Claim for Attorneys’ Fees and Expenses in connection with Lawsuit Pending in the Delaware Court of Chancery captioned Thompson v. QXO, Inc., C.A. No. 2026-0757-BWD (Del. Ch.)
The rest of this wire is for subscribers
Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.
7 days, no card required.
Read releases like this the second they cross the wire.
1,400+ feeds — live on PPN World right now. Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.
Start the free trial →Your announcement next? Distribute your press release to the global wires with PPN Source — and track its pickup live here.
PPN Source →